07:00 , Jul 15, 2013 |  BC Week In Review  |  Company News

Griffin Discoveries, Sensorion neurology news

The companies received a €1.1 million ($1.4 million) grant from the Eureka Eurostars program to develop new therapies for vestibular diseases, which include Meniere's disease and vertigo crisis. The companies will jointly map the function...
07:00 , Apr 8, 2013 |  BioCentury  |  Emerging Company Profile

Ziarco: Scratching the allergic itch

Ziarco Pharma Ltd. emerged last year from a shuttered Pfizer Inc. R&D site in Sandwich, U.K., with a quartet of allergy and inflammation assets that otherwise would have been shelved and forgotten. The biotech's lead...
07:00 , Jul 29, 2010 |  BC Innovations  |  Targets & Mechanisms

Son of Dimebon

When Medivation Inc. 's Dimebon latrepirdine failed in a Phase III trial in Alzheimer's disease, it came as no surprise to skeptics of the compound who had long doubted the generic antihistamine, for which a...
07:00 , Jul 27, 2009 |  BioCentury  |  Product Development

Parsing the Dimebon spike

Elevated beta amyloid is generally believed to be one of the causal mechanisms in the pathology of Alzheimer's disease. Thus it was surprising when data presented at this month's International Conference on Alzheimer's Disease in...
08:00 , Feb 14, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Malaria (strains Plasmodium berghei NK65 (Pb NK65) and Plasmodium berghei ANKA (PbA)) Histamine H1 receptor; histamine H2 receptor; histidine decarboxylase...
07:00 , Mar 26, 2007 |  BioCentury  |  Product Development

Reaching proof of concept

Reaching proof of concept Obesity Company Product Description Target/ Mechanism Milestones Alizyme Cetilistat (ATL-962) Lipase inhibitor Lipase Start Ph III 1H07 (A) Amylin Pramlintide/leptin Synthetic amylin analog/recombinant leptin Amylin receptor/leptin receptor Ph II data 07...
08:00 , Nov 6, 2006 |  BioCentury  |  Strategy

A shelf full of antihistamines

With its newly licensed oral histamine H1 receptor antagonist, Inspire Pharmaceuticals Inc. thinks it can cover the delivery preferences of patients in the crowded allergy space. Inspire (ISPH, Durham, N.C.) last week obtained U.S. and...
08:00 , Feb 27, 2006 |  BC Week In Review  |  Company News

Inspire, Boehringer Ingelheim deal

Boehringer granted ISPH exclusive rights to develop and market intranasal epinastine in the U.S. and Canada to treat or prevent rhinitis. ISPH expects to start a Phase II trial this year. Boehringer will receive an...
02:23 , Feb 22, 2006 |  BC Extra  |  Company News

Inspire, Boehringer epinastine deal

Boehringer Ingelheim (Ingelheim, Germany) granted ISPH exclusive rights to develop and market intranasal epinastine in the U.S. and Canada to treat or prevent rhinitis. ISPH expects to start a Phase II trial this year. Boehringer...
07:00 , Sep 26, 2005 |  BioCentury  |  Product Development

Ticking off inflammation

Over millions of years, ticks have evolved an ability to remain undetected on humans for several weeks while they enjoy a blood meal. They achieve this by injecting a cocktail of molecules into the skin...